Jim Petrik, University of Guelph

Research

Crc Advanced Stage Disease Combination Therapy Immunotherapy Metronomic Chemotherapy Ovarian Cancer Pdx Models Of Ovarian Cancer Translational Ovarian Cancer Research

Latest papers

Prenatal cannabis smoke exposure alters placental development in a murine model of pregnancy
PLoS ONE · 2026
HER2-driven mammary tumorigenesis enhances bioenergetics despite reductions in mitochondrial content
eLife · 2026
Development and Evaluation of the Firefighter Exposure to Carcinogens Scale.
Journal of occupational and environmental medicine · 2025

All 35 publications

Latest funding

Fc3TSR improves efficacy of immune checkpoint inhibitor therapy in an orthotopic, syngeneic mouse model advanced-stage epithelial ovarian cancer
CIHR · 2025 · Supervisor
$1,500
Combining tumour microenvironment remodelling and low dose metronomic chemotherapy to enhance treatment efficacy and preserve ovarian function and fertility in advanced stage cancers
CIHR · 2025 · Supervisor
$120,000
Evaluation of pharmacologic LKB1 inhibition as a new therapeutic strategy against ovarian cancer metastasis
CIHR · 2024 · Co-investigator
$879,750

All 14 grants and awards

35 publications.

01

Prenatal cannabis smoke exposure alters placental development in a murine model of pregnancy

Podinic T, Sunil M, MacAndrew A, Monaco C, Lee G, Lockington C, Petrik J, Lucas A-M, Tomy T, Tomy G

PLoS ONE20262 citations

DOI: 10.1371/journal.pone.0328123

02

HER2-driven mammary tumorigenesis enhances bioenergetics despite reductions in mitochondrial content

Frangos SM, Brunetta HS, Wang D, Jabile MJT, Jeffries LM, Mencfeld G, WL D, Muller WJ, Khursigara CM, Fisher-Wellman KH

eLife20261 citations

DOI: 10.7554/elife.104079

03

Development and Evaluation of the Firefighter Exposure to Carcinogens Scale.

McGrath PJ, Akbari-Fakhrabadi M, Chaplin WF, Saryeddine T, Pawlett G, Laroche E, Petrik J, Irwin I, Caban-Martinez AJ, Hervieux V, Xiong T, McDonald MK, Wang J, Yakovenko I

Journal of occupational and environmental medicine2025

DOI: 10.1097/jom.0000000000003515 PMID: 40992385

04

Mitochondrial-targeted plastoquinone therapy prevents early onset muscle weakness that occurs before atrophy during ovarian cancer

Delfinis LJ, Khajehzadehshoushtar S, Flewwelling LD, Andrews NJ, Garibotti MC, Gandhi S, Brahmbhatt AN, Morris BA, Garlisi B, Lauks S

Molecular Metabolism20255 citations

DOI: 10.1016/j.molmet.2025.102211

05

The mitochondrial‐targeted antioxidant SkQ1 prevents skeletal muscle mitochondrial‐apoptotic but not necroptotic signalling during ovarian cancer

Khajehzadehshoushtar S, Delfinis LJ, Rahman FA, Garibotti MC, Gandhi S, Brahmbhatt AN, Morris BA, Garlisi B, Lauks S, Aitken C

Journal of Physiology20254 citations

DOI: 10.1113/jp287912

06

Loss of Trp53 results in a hypoactive T cell phenotype accompanied by reduced pro-inflammatory signaling in a syngeneic orthotopic mouse model of ovarian high-grade serous carcinoma

Haagsma J, Valdes YR, Ou X, Rashu R, Haeryfar SMM, Petrik J, Shepherd TG

Oncotarget2025

DOI: 10.18632/oncotarget.28768

07

The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities

Garlisi B, Lauks S, Aitken C, Ogilvie LM, Lockington C, Petrik D, Eichhorn JS, Petrik J

Current Oncology202483 citationsSenior author

DOI: 10.3390/curroncol31070283

08

Muscle weakness and mitochondrial stress occur before severe metastasis in a novel mouse model of ovarian cancer cachexia

Delfinis LJ, Ogilvie LM, Khajehzadehshoushtar S, Gandhi S, Garibotti MC, Thuhan AK, Matuszewska K, Pereira M, Jones RG, Cheng AJ

Molecular Metabolism202418 citations

DOI: 10.1016/j.molmet.2024.101976

09

Cardiac Atrophy, Dysfunction, and Metabolic Impairments A Cancer-Induced Cardiomyopathy Phenotype

Ogilvie LM, Delfinis LJ, Coyle-Asbil B, Vudatha V, Alshamali R, Garlisi B, Pereira M, Matuszewska K, Garibotti MC, Gandhi S

American Journal of Pathology202411 citations

DOI: 10.1016/j.ajpath.2024.06.008

10

Therapy-naïve malignancy causes cardiovascular disease: a state-of-the-art cardio-oncology perspective

Ogilvie LM, Coyle-Asbil B, Brunt KR, Petrik J, Simpson JA

American Journal of Physiology. Heart and Circulatory Physiology20248 citations

DOI: 10.1152/ajpheart.00795.2023

Fc3TSR improves efficacy of immune checkpoint inhibitor therapy in an orthotopic, syngeneic mouse model advanced-stage epithelial ovarian cancer

SupervisorCIHR2025Travel Awards - Institute Community Support

Principal investigators: Jeffries, Leslie M

Keywords: Ics Travel Awards

$1,500

Combining tumour microenvironment remodelling and low dose metronomic chemotherapy to enhance treatment efficacy and preserve ovarian function and fertility in advanced stage cancers

SupervisorCIHR2025DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

Principal investigators: Lockington, Cielle I

Keywords: Female Infertility; Fertility Preservation; Metronomic Chemotherapy; Oncofertility; Ovarian Cancer; Pancreatic Cancer

$120,000

Evaluation of pharmacologic LKB1 inhibition as a new therapeutic strategy against ovarian cancer metastasis

Co-investigatorCIHR2024Project Grant

Principal investigators: Shepherd, Trevor G

Keywords: Chemoresistance; Lkb1; Mouse Models; Organoid; Organotypic Models; Ovarian Cancer; Spheroid; Stress Signalling; Therapeutics Testing

$879,750

Enhancing anti-tumour immune responses in advanced ovarian cancer through the modulation of tumour-associated macrophages

SupervisorCIHR2024CIHR Fellowship

Principal investigators: Jeffries, Leslie M

Keywords: Immunosuppression; Lipid Metabolism; Ovarian Cancer; Patient-Derived Organoids; Tumour Microenvironment; Tumour-Associated Macrophages

$210,000

Maintaining and Enhancing Flow Cytometry Capacity for Biological Research at the University of Guelph

Co-investigatorNSERC2023Research Tools and Instruments

Principal investigators: Wootton, Sarah

$150,000

Canada Research Chairs - Tier 1

Nominated PICIHR2022Canada Research Chairs - CIHR Funded - Tier 1

Principal investigators: Petrik, Jim J

Keywords: Crc

$1,400,000

Interrogating the critical requirement of intact LKB1-NUAK1 signaling during the ovarian tumorigenic program

Co-investigatorCIHR2020Project Grant

Principal investigators: Shepherd, Trevor G

Keywords: Cell Adhesion; Lkb1; Metastasis; Nf Kappa B; Nuak1; Ovarian Cancer; Oxidative Stress; Patient-Derived Organoids; Spheroid; Tumour Allografts

$749,700

Vascular normalization improves immunotherapy in advanced stage ovarian cancer.

Nominated PICIHR2019Project Grant

Principal investigators: Petrik, Jim J

Keywords: Advanced Stage Disease; Combination Therapy; Immunotherapy; Metronomic Chemotherapy; Ovarian Cancer; Pdx Models Of Ovarian Cancer; Translational Ovarian Cancer Research; Tumor Immunosuppression; Vascular Normalization

$631,126

Regulation of Angiogenesis in Mammalian Ovaries

Principal investigatorNSERC2015Discovery Grants Program - Individual

Principal investigators: Petrik, Jim

$120,000

Thrombospondin-1 as a potent anti-tumor and anti-angiogenic factor in ovarian cancer

Nominated PICIHR2011Operating Grant

Principal investigators: Petrik, Jim J

Keywords: Angiogenesis; Animal Model Of Ovarian Cancer; Anti-Angiogenic Therapy; Chemotherapy; Ovarian Cancer

$549,816

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Frequent collaborators

Medicine
Biomedical Sciences
Obstetrics & Gynecology
Pediatrics
Pathology & Molecular Medicine
Obstetrics and Gynecology
Psychology and Neuroscience
Other

1 shared papers, latest 2026

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2022

Subject: Prospective PhD student: Crc Dear Professor Petrik, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Prenatal cannabis smoke exposure alters placental development in a murine model of pregnancy" (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Canada Research Chairs - Tier 1" (2022), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]